“The study provides the first evidence of…interaction between CBD and clobazam that could contribute to improved outcomes in patients with Dravet syndrome.“
History was made in 2017 when the New England Journal of Medicine published the remarkable results of multi-year, multi-centre clinical trials involving children as young as three who suffered life-threatening forms of epilepsy.
The groundbreaking research involved adding CBD to anti-seizure medication, some of which were clobazam and valproate.
In a new study published this week in Epilepsia, Australian scientists explain their discovery that: “CBD and clobazam together, produced an anticonvulsant effect …that was greater than that observed with either CBD or clobazam alone.”
“CBD and clobazam together, produced an anticonvulsant effect …that was greater than that observed with either CBD or clobazam alone.”
The researchers also said that the combination of clobazam and CBD “resulted in a lower proportion of mice experiencing spontaneous seizures than with clobazam alone.”
The only cannabis-derived drug ever approved in the FDA’s 88-year history is Epidiolex
In a 2017 review of the clinical trials that led to Epidiolex, the Journal of Epilepsy Research noted that 66% of patients in the CBD group were also taking clobazam and other anti-epileptic drugs during the clinical trials, so it was unclear how that may have affected the outcomes.
It was possible, they hypothesized, that Epidiolex’s efficacy was driven not by CBD alone, but rather by a combination of CBD and seizure medications already being taken by participants.
It seems they were right.